The use of unlicensed and off-label medicines in the neonate
The use of unlicensed and off-label medicines in the neonate
复制标题
DOI：
10.1016/j.siny.2004.11.003
复制
发表时间：
2005-04-01
影响因子：
3
通讯作者：
McIntyre, J
中科院分区：
文献类型：
--
作者：
Conroy, S;McIntyre, J
在重症监护室的新生儿中使用未经许可和标签外的药物是普遍和普遍的。高达93%的婴儿在重症监护期间至少接受一种未经许可或标签外的药物。这种做法是他们护理的重要组成部分，应该根据现有的最佳证据进行。然而，由于缺乏适当的信息和获得许可的新生儿药物配方，每天都会出现问题。这些问题包括选择适当的药物和剂量、给药以及用药错误的风险增加。改善这种状况的举措正在美国展开，欧洲也在提议。然而，需要采取更紧迫的行动，以阻止这些婴儿继续被剥夺获得安全、有效和高质量治疗的基本人权。(C)2004爱思唯尔有限公司。保留所有权利。
The use of unlicensed and off-label medicines in neonates in intensive care is common and widespread. Up to 93% of babies receive at least one unlicensed or off-label medicine during their stay in intensive care. Such practice is an essential part of their care and should be done based on the best evidence available. However, problems arise - on an every-day basis - because of the lack of appropriate information and licensed medicine formulations for neonates. These problems include the selection of appropriate medicine and dose, administration and the increased risk of medication errors. Initiatives to improve the situation are underway in the US and are proposed in Europe. However, more urgent action is required to stop these babies continuing to be deprived of their basic human rights to safe, effective and high-quality therapy. (c) 2004 Elsevier Ltd. All rights reserved.